Clostridium News and Research

RSS

Auxilium Pharmaceuticals’ net revenues increase $125.9M to 56%

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced financial results for the fourth quarter and full year ending December 31, 2013. The Company also highlighted select commercial, regulatory and clinical development progress and future goals and provided financial guidance for 2014.

28 Feb 2014

Researchers identify components of C. diff bacteria that can be used to develop better treatment

Rhode Island Hospital researchers have identified components in Clostridium difficile (C. diff) that may lead to new diagnostic tools, and ultimately more timely and effective treatment for this often fatal infection. C. diff is a spore-forming bacterium that causes severe diarrhea and is responsible for 14,000 deaths annually in the U.S. The study is published online in advance of print in the Journal of Molecular Diagnostics.

31 Jan 2014

Llama-derived antibodies open door to development of new treatments for C. difficile infections

Researchers from the Alberta Glycomics Centre at the University of Calgary and the University of Alberta, in collaboration with researchers at the National Research Council of Canada in Ottawa, have revealed the first molecular views showing how highly specific antibodies derived from llamas may provide a new method for controlling deadly infections from the opportunistic bacterial pathogen Clostridium difficile (C. difficile).

31 Jan 2014

HHS develops national plan to prevent Healthcare-Associated Infections

Independent evaluators have found that measurable progress in reducing the rates of some targeted HAIs has been achieved under the umbrella of a national plan to prevent HAIs that was developed by the U.S. Department of Health and Human Services (HHS).

24 Jan 2014

Erosive GERD treatments: an interview with Professor Joaquim Moraes-Filho, University of São Paulo Medical School

Gastroesophageal Reflux Disease (GERD) is a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications.

20 Jan 2014

IBM and OhioHealth collaborate to aid in prevention of infections in hospitals

OhioHealth and IBM today announced a collaboration to aid in the prevention of infections using a first-of-a-kind network of wireless sensors and real-time Big Data analytics that measure hand-washing practices.

10 Jan 2014

Auxilium Pharmaceuticals reports interim data from XIAFLEX Phase 4 study in patients with DC

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced that interim data from its Phase 4 retreatment study (AUX-CC-862) evaluating XIAFLEX (collagenase clostridium histolyticum or CCH) in adult patients with Dupuytren's contracture and a recurrent contracture with a palpable cord will be presented for the first time at the American Association for Hand Surgery 2014 Annual Meeting being held January 8-11, 2014 in Kauai, Hawaii.

9 Jan 2014

Healthcare workers' hands contaminated with C. difficile after routine care, study shows

A new study finds nearly one in four healthcare workers' hands were contaminated with Clostridium difficile spores after routine care of patients infected with the bacteria. The study was published in the January issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.

24 Dec 2013

Genetic screening identifies genes driving resistance with guide RNA library

Researchers have developed a method to create a comprehensive library of mutations across all genes in the mouse genome. This library can be used to examine the role of every gene in different cell types.

23 Dec 2013

Auxilium seeks FDA approval for XIAFLEX sBLA to treat multiple Dupuytren's contracture cords concurrently

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration requesting approval of XIAFLEX (collagenase clostridium histolyticum, or CCH) for the treatment of multiple Dupuytren's contracture cords concurrently.

20 Dec 2013

Illinois healthcare coalition receives $7M grant to establish research network to battle chronic illnesses

Governor Quinn today announced that a coalition of 20 health and hospital organizations from Illinois has been awarded an 18-month, $7million federal award to establish a clinical data research network.

17 Dec 2013

Auxilium doses first patient in CCH Phase 2b study for treatment frozen shoulder syndrome

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in the EU, today announced that its partner Auxilium Pharmaceuticals, Inc. has dosed the first patient in its Phase 2b study of collagenase clostridium histolyticum for the treatment of frozen shoulder syndrome (adhesive capsulitis).

16 Dec 2013

Auxilium Pharmaceuticals' XIAFLEX gets FDA approval for treatment of Peyronie's disease

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.

6 Dec 2013

C. difficile doesn’t harm infants, but serves as a reservoir to affect adults

Infants and toddlers frequently carry toxigenic Clostridium difficile, usually with no harm to themselves, but can serve as a reservoir and spread the bacteria to adults in whom it can cause severe disease, according to a study by a team of Swedish researchers published ahead of print in the Journal of Clinical Microbiology.

4 Dec 2013

PrimeraDx gets FDA clearance for ICEPlex C. difficile Assay Kit and ICEPlex System

PrimeraDx, a molecular diagnostics company, announced today that the ICEPlex C. difficile Assay Kit and the ICEPlex System have received 510(k) clearance from the United States Food and Drug Administration.

3 Dec 2013

Restoring helpful bacteria of the gut and intestines may treat patients with RCDI, find scientists

Scientists at the Institute for Genome Sciences at the University of Maryland School of Medicine and physicians at Sinai Hospital, Baltimore, MD, have found that restoring the normal, helpful bacteria of the gut and intestines may treat patients suffering from recurrent Clostridium difficile infections. Transplanting fecal matter of healthy donors into patients with recurrent C. difficile infection appears to restore normal bacterial composition and resolve infection.

27 Nov 2013

Habitual dietary intake of monozygotic twins associated with fecal microbiota composition

The establishment of microbial populations in the gastrointestinal-tract is a complex process, involving microbial and host interactions eventually resulting in a dense and stable population.

18 Nov 2013

Government spending cuts within NHS increase risk of Clostridium difficile infection

72% of clinicians believe that Government spending cuts within the NHS increase the risk of hospital acquired infections. The ‘Think C-differently’ report, which advises on the current Clostridium difficile landscape, found that despite stringent measures to manage and control Clostridium difficile infection, the NHS is still battling to keep infection rates to a minimum.

8 Nov 2013

Researchers identify obesity as possible risk factor for clostridium difficile infection

Researchers from Boston Medical Center and Boston University School of Medicine have identified obesity as a possible risk factor for clostridium difficile infection. These findings, which appear online in Emerging Infectious Diseases, may contribute to improved clinical surveillance of those at highest risk of disease.

25 Oct 2013

Researchers identify C. perfringens type B bacteria believed to trigger multiple sclerosis

A research team from Weill Cornell Medical College and The Rockefeller University has identified a bacterium it believes may trigger multiple sclerosis, a chronic, debilitating disorder that damages myelin forming cells in the brain and spinal cord.

18 Oct 2013